| Literature DB >> 19519501 |
Sante Cundari1, Guido Cavaletti.
Abstract
IMiDs compounds are a class of analogues of thalidomide, with greater immunomodulatory activity and a superior safety profile compared to the parent compound. They show substantial increase in potency and an interesting tolerability profile, primarily due to a decreased incidence of the most severe side effect of thalidomide, i.e. Chemotherapy-Induced Peripheral Neurotoxicity (CIPN). These novel aspects of the IMiDs compounds will be discussed.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19519501 DOI: 10.2174/138955709788452595
Source DB: PubMed Journal: Mini Rev Med Chem ISSN: 1389-5575 Impact factor: 3.862